Glioma-targeting micelles for optical/magnetic resonance dual-mode imaging

Abstract

Surgical resection is the primary mode for glioma treatment, while gross total resection is difficult to achieve, due to the invasiveness of the gliomas. Meanwhile, the tumor-resection region is closely related to survival rate and life quality. Therefore, we developed optical/magnetic resonance imaging (MRI) bifunctional targeted micelles for glioma so as to delineate the glioma location before and during operation. The micelles were constructed through encapsulation of hydrophobic superparamagnetic iron oxide nanoparticles (SPIONs) with polyethylene glycol- block -polycaprolactone (PEG- b -PCL) by using a solvent-evaporation method, and modified with a near-infrared fluorescent probe, Cy5.5, in addition to the glioma-targeting ligand lactoferrin (Lf). Being encapsulated by PEG- b -PCL, the hydrophobic SPIONs dispersed well in phosphate-buffered saline over 4 weeks, and the relaxivity ( r 2 ) of micelles was 215.4 mM −1 ·s −1 , with sustained satisfactory fluorescent imaging ability, which might have been due to the interval formed by PEG- b -PCL for avoiding the fluorescence quenching caused by SPIONs. The in vivo results indicated that the nanoparticles with Lf accumulated efficiently in glioma cells and prolonged the duration of hypointensity at the tumor site over 48 hours in the MR image compared to the nontarget group. Corresponding with the MRI results, the margin of the glioma was clearly demarcated in the fluorescence image, wherein the average fluorescence intensity of the tumor was about fourfold higher than that of normal brain tissue. Furthermore, 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide assay results showed that the micelles were biocompatible at Fe concentrations of 0–100 μg/mL. In general, these optical/MRI bifunctional micelles can specifically target the glioma and provide guidance for surgical resection of the glioma before and during operation.

Agents for fluorescence-guided glioma surgery: a systematic review of preclinical and clinical results

“…Thirty studies described the results of fluorescent agents in a pre-clinical phase (Table 2) [2, 4, 7, 8, 10, 18–21, 32, 43, 45–48, 51, 55, 61, 68, 73, 77, 83, 90, 91, 104, 108, 111, 112, 116, 121]. Within this group of fluorescent agents, a broad distinction could be made between molecular fluorophores and nanoparticles.…”

“…Pre-clinically, 18 studies evaluated molecular fluorophores [2, 4, 7, 18, 20, 21, 32, 43, 45, 55, 61, 77, 91, 104, 111, 112, 116] and 12 studies evaluated nanoparticles [10, 19, 46–48, 51, 68, 73, 83, 90, 108, 121]. Four of these 30 studies evaluated fluorophores or nanoparticles bound to EGF or anti-EGFR antibodies [21, 48, 90, 91].…”

Magnetite nanoparticles for cancer diagnosis, treatment, and treatment monitoring: recent advances

“…Multimodal imaging enhancement agents allow investigators and physicians to use NPs on a number of imaging platforms including magnetic resonance 49 , optical 50 , CT 41 , PET 51 , photoacoustic 52 , and other imaging systems 53 . Each of the imaging methods has benefits and drawbacks.…”

Micellar emulsions composed of mPEG-PCL/MCT as novel nanocarriers for systemic delivery of genistein: a comparative study with micelles

“…24 Briefly, Gen, MCT, and mPEG-PCL at the ratio of 4/5/50 (w/w) were dissolved in hot absolute ethanol, and then rapidly injected into deionized water (1:5, v/v) under agitation. Self-assembly occurred upon the solvent diffusion into the aqueous phase, resulting in formation of Gen-MEs.…”